Soligenix, Inc., a biopharmaceutical company specializing in rare diseases, has announced progress in its confirmatory Phase 3 HyBryte™ clinical trial for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The trial, known as FLASH2, is actively enrolling 80 patients and is on track to deliver top-line results in the second half of 2026. This study is a continuation of a previous Phase 3 trial, with adjustments to the primary endpoint assessment period. Further updates on enrollment progress are expected later this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.